• Salary in the range of £28,500 - £38,000 dependent upon qualifications and experience.
• Job Ref: MI/14/21
• Duration of post: 3 Years

The Cancer Research UK Manchester Institute is a centre for excellence in cancer research (www.cruk.manchester.ac.uk). We occupy state-of-the-art laboratories and provide exceptional core facilities, including next generation sequencing, mass-spectrometry, advanced imaging, bioinformatics, histology, and flow cytometry. We are core-funded by Cancer Research UK (www.cancerresearchuk.org), the world’s largest cancer organisation, are an Institute of The University of Manchester (www.manchester.ac.uk), and are adjacent to The Christie NHS Foundation Trust (www.christie.nhs.uk), one of the largest cancer treatment centres in Europe. These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes in a vibrant and dynamic city surrounded by beautiful countryside and with excellent national and international transport links. 

An exciting opportunity has arisen for a post-doctoral scientist within Prof. Caroline Dive’s Clinical and Experimental Pharmacology Group. The research within the preclinical pharmcology team will focus on our unique small cell lung cancer (SCLC) circulating tumour cell (CTC) derived explant tumour models (CDX) and analysis of CTCs isolated from SCLC patients. The successful candidate will investigate the contribution of epithelial to mesenchymal transition and cell co-operation in the haematological dissemination of lung cancer with a focus on circulating tumour microemboli (cell clusters).

You will have a PhD in oncology, cell biology or molecular pharmacology and have a strong desire to see their research translated for patient benefit.

The deadline for receipt of applications is: 23 March 2014.